Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Churcher

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|January 31, 2006
In vivo characterization of Abeta(40) changes in brain and cerebrospinal fluid using the novel gamma-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) in the ratJonathan D Best, Mark T Jay, Franklin Otu, et al.
Bioorganic & Medicinal Chemistry Letters|December 17, 2002
A new series of potent benzodiazepine gamma-secretase inhibitorsIan Churcher, Kate Ashton, John W Butcher, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|October 7, 2017
Synthesis and Demonstration of the Biological Relevance of sp<sup>3</sup> -rich Scaffolds Distantly Related to Natural Product FrameworksDaniel J Foley, Philip G E Craven, Patrick M Collins, et al.
Journal of Medicinal Chemistry|May 30, 2003
Design and synthesis of highly potent benzodiazepine gamma-secretase inhibitors: preparation of (2S,3R)-3-(3,4-difluorophenyl)-2-(4-fluorophenyl)-4- hydroxy-N-((3S)-1-methyl-2-oxo-5- phenyl-2,3-dihydro-1H-benzo[e][1,4]-diazepin-3-yl)butyramide by use of an asymmetric Ireland-Claisen rearrangementIan Churcher, Susie Williams, Sonia Kerrad, et al.
ACS Chemical Biology|July 23, 2020
Structural Insights into PROTAC-Mediated Degradation of Bcl-xLChun-Wa Chung, Han Dai, Esther Fernandez, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 14, 2006
The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouseJonathan D Best, David W Smith, Michael A Reilly, et al.
Journal of Medicinal Chemistry|March 4, 2016
Structurally Diverse Mitochondrial Branched Chain Aminotransferase (BCATm) Leads with Varying Binding Modes Identified by Fragment ScreeningJennifer A Borthwick, Nicolas Ancellin, Sophie M Bertrand, et al.
Journal of Medicinal Chemistry|August 25, 2021
Optimization of a Series of RIPK2 PROTACsAfjal H Miah, Ian E D Smith, Mark Rackham, et al.
ACS Chemical Biology|September 12, 2018
Modulating PCAF/GCN5 Immune Cell Function through a PROTAC ApproachZuni I Bassi, Martin C Fillmore, Afjal H Miah, et al.
Drug Discovery Today|September 21, 2013
A practical drug discovery project at the undergraduate levelM Jonathan Fray, Simon J F Macdonald, Ian R Baldwin, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
The Journal of Pharmacology and Experimental Therapeutics|January 31, 2006
In vivo characterization of Abeta(40) changes in brain and cerebrospinal fluid using the novel gamma-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) in the ratJonathan D Best, Mark T Jay, Franklin Otu, et al.
Bioorganic & Medicinal Chemistry Letters|December 17, 2002
A new series of potent benzodiazepine gamma-secretase inhibitorsIan Churcher, Kate Ashton, John W Butcher, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|October 7, 2017
Synthesis and Demonstration of the Biological Relevance of sp<sup>3</sup> -rich Scaffolds Distantly Related to Natural Product FrameworksDaniel J Foley, Philip G E Craven, Patrick M Collins, et al.
Journal of Medicinal Chemistry|May 30, 2003
Design and synthesis of highly potent benzodiazepine gamma-secretase inhibitors: preparation of (2S,3R)-3-(3,4-difluorophenyl)-2-(4-fluorophenyl)-4- hydroxy-N-((3S)-1-methyl-2-oxo-5- phenyl-2,3-dihydro-1H-benzo[e][1,4]-diazepin-3-yl)butyramide by use of an asymmetric Ireland-Claisen rearrangementIan Churcher, Susie Williams, Sonia Kerrad, et al.
ACS Chemical Biology|July 23, 2020
Structural Insights into PROTAC-Mediated Degradation of Bcl-xLChun-Wa Chung, Han Dai, Esther Fernandez, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 14, 2006
The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouseJonathan D Best, David W Smith, Michael A Reilly, et al.
Journal of Medicinal Chemistry|March 4, 2016
Structurally Diverse Mitochondrial Branched Chain Aminotransferase (BCATm) Leads with Varying Binding Modes Identified by Fragment ScreeningJennifer A Borthwick, Nicolas Ancellin, Sophie M Bertrand, et al.
Journal of Medicinal Chemistry|August 25, 2021
Optimization of a Series of RIPK2 PROTACsAfjal H Miah, Ian E D Smith, Mark Rackham, et al.
ACS Chemical Biology|September 12, 2018
Modulating PCAF/GCN5 Immune Cell Function through a PROTAC ApproachZuni I Bassi, Martin C Fillmore, Afjal H Miah, et al.
Drug Discovery Today|September 21, 2013
A practical drug discovery project at the undergraduate levelM Jonathan Fray, Simon J F Macdonald, Ian R Baldwin, et al.
Pageof 4